Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
about
Therapy of human papillomavirus-related diseaseAntigen-specific immunotherapy of cervical and ovarian cancerAntigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.Immunotherapy for cervical cancer: Research status and clinical potentialA conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaImproving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activationEnhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection.Immune therapy for human papillomaviruses-related cancers.Oral vaccination: where we are?Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand.Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 proteinSafety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.Design of multi-epitope, analogue-based cancer vaccines.Tumor-associated antigens: from discovery to immunity.Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.Preventative and therapeutic vaccines for cervical cancer.Therapeutic Vaccine Strategies against Human Papillomavirus.Recent developments in human papillomavirus vaccines.Progress in the development of a cervical cancer vaccine.Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsTrial watch: Peptide vaccines in cancer therapyHuman papillomavirus infection: an old disease, a new vaccine.Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.Human papillomavirus therapeutic vaccines in head and neck tumors.Advances in dendritic-cell-based therapeutic vaccines for cervical cancer.Therapeutic vaccines against human papillomavirus and cervical cancer.A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Cancer immunotherapy and nanomedicine.Vaccines as consolidation therapy for myeloid leukemia.Updates in systemic treatment for metastatic cervical cancer.The potential of plants for the production and delivery of human papillomavirus vaccines.Novel Approaches for Vaccination Against HPV-Induced Cancers.Cancer immunotherapy.Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx.
P2860
Q27007473-3C80D832-FBEE-4BAD-99C2-ADC5E8BC5326Q27488697-1825B877-C118-450D-B91C-D2B4C177F9DBQ33942149-1E2D3DF3-5E1D-403B-9B99-7E2DC2329E20Q33981920-72389F5C-CA63-4322-B560-D1C49262DD95Q34033763-F4D0153F-A5F5-4FC8-89E3-9851FE94C703Q34121681-FC1AC49E-6213-4F4E-B0FC-C8C1944AFB53Q34181954-705D598B-39F6-48CE-AAB5-AC0E7E36AA2DQ34397856-47281063-11A8-47D2-8C03-C574CAAEC325Q34516610-ACCECDB2-8523-4B8E-B2EB-DB3705A5E51FQ34657561-BFE00D51-BCF4-46F3-A0BA-EF694E8C7EFBQ34660422-3ABCB24A-3DC8-4642-B45E-49C2306B3760Q34712905-52AB854A-5312-4CDB-8393-CF6424654770Q34975376-094C44B2-B083-421A-9424-0BE576E03219Q35055665-58744745-1B33-4828-8854-4202D07EE458Q35194178-2015109B-7E66-4A6A-A7DE-B7D8629AA0B2Q35207535-871F1956-6CD5-45A5-A0D8-A405B85D24B8Q35214398-BD108338-E7F7-499E-857A-0E2AD136EB70Q35552591-517176C7-9F81-4CE4-B10B-F976A2054B17Q35623323-E1801B49-5E01-46C8-A433-607CBAF40A0BQ35826752-901AD0FA-2778-454B-98D4-EAC691FC5395Q35842528-D0E672F7-1181-4B59-81C8-914C3025C951Q35919119-3415ED0B-F966-4EF5-80B9-ECF5D83FBF19Q36011425-EFFB2FBB-928D-437C-A08C-71F275015FF4Q36476100-F41F128E-C27F-49D5-AD3A-5CC73983185FQ36480555-E8EDD88F-53A3-4A2C-AC51-4A10B7635F38Q36625526-2C846A9B-9A59-41C5-84DC-D82496BE0866Q36746876-0B266EB0-9BD9-4253-8209-50DA31ED6F4FQ36817148-938C11E3-F88C-4E63-B109-C23D48049855Q36974722-1F96FD19-5E24-4EAC-B89A-3DE725BD3FB5Q37418916-D530F713-614A-4F9F-AACA-AF4A5B807683Q37434590-EB16D77A-73AE-4E5E-AF26-8DDA9285BF71Q37579334-3318743B-CE7B-4EFF-98A6-1EBEE3C380B7Q37785836-B24C42C0-D709-4B30-8E23-8F941AC14BE9Q37842342-BEE184C5-1557-4220-9E8A-438E48CC2962Q38178824-AA9260BD-1C8A-4C71-BC8C-A87C12C04A66Q38424974-5B820701-3349-4B55-8945-04E5C4933D79Q39033362-03722A86-5DA1-4B88-8138-7FE6F69219D7Q39958332-BF63D745-56A1-45E3-A0EA-13AA0CCE5542Q40252793-0A247246-68A8-4A81-91F6-7F6EF2A3F653Q40351911-A233BE67-84EC-47D6-AB18-9B052E5B6107
P2860
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Detection of T helper response ...... ients with cervical carcinoma.
@en
type
label
Detection of T helper response ...... ients with cervical carcinoma.
@en
prefLabel
Detection of T helper response ...... ients with cervical carcinoma.
@en
P2093
P1476
Detection of T helper response ...... tients with cervical carcinoma
@en
P2093
B J Trimbos
C J Melief
G G Kenter
G J Fleuren
J H de Jong
M E Ressing
P Hoogerhout
P304
P356
10.1097/00002371-200003000-00010
P577
2000-03-01T00:00:00Z